Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cadherin EGF LAG seven-pass G-type receptor 2 (CELSR2) is a large membrane protein with nine cadherin ectodomains, several EGF-like domains, and a seven-pass transmembrane region typical of adhesion GPCRs. It mediates essential processes such as planar cell polarity, tissue morphogenesis, neural wiring, and cilia organization in vertebrates. As part of the noncanonical Wnt/PCP signaling pathway, CELSR2 organizes and stabilizes cell–cell contacts, regulates migration and axon guidance of neurons, and may impact lipid metabolism and cardiovascular risk. Alterations in CELSR2 function or expression are associated with defects in embryonic development, adult synaptic integrity, dyslipidemia, and possibly other diseases. Research continues to elucidate its therapeutic potential and mechanistic roles[1][2][3][5].
Not applicable for approved drugs. Mechanistically, therapeutic targeting would likely involve modulation of cell adhesion and PCP signaling.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cadherin EGF LAG seven-pass G-type receptor 2 (CELSR2).